Your AI-Trained Oncology Knowledge Connection!
John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising findings from the phase III RESONATE trial that compared ofatumumab to ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.
MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, resulting in the first breakthrough therapy designation from the FDA for a treatment in this setting.
Adding the VEGFR-2 inhibitor ramucirumab to standard docetaxel improved overall survival by 1.4 months versus docetaxel alone in patients with advanced non–small cell lung cancer.
Mark D. Pegram, MD, from the Stanford University Medical Center, discusses a phase II study of margetuximab in patients with relapsed or refractory advanced breast cancer whose tumors express HER2 at the 2+ level by immunohistochemistry and lack evidence of HER2 gene amplification by FISH.
Combining the oral targeted agents olaparib and cediranib resulted in a near-doubling of median progression-free survival (PFS) among women with recurrent ovarian cancer in a phase II study highlighted Saturday during the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.
Treatment with single-agent ibrutinib dramatically increased PFS by nearly 80% and significantly extended OS by 57% compared with ofatumumab in patients with relapsed or refractory CLL.
Lenvatinib, a novel multityrosine kinase inhibitor, is highly effective against differentiated thyroid cancer that has become resistant to standard RAI therapy.
Patients with less aggressive, HPV-positive oropharyngeal cancer can be effectively treated with a lower-dose radiation regimen depending upon their response to combination induction therapy.
Denise A. Yardley, MD, hematologist/oncologist, Sarah Cannon Research Institute discusses a pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer when given enzalutamide plus exemestane.
Adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.
A phone-based intervention that offers practical tools to help family caregivers support their loved one with advanced cancer-as well as emphasizing the importance of maintaining a healthy lifestyle themselves-resulted in less caregiver depression and better quality of life, according to the findings of a new study presented May 30 at the 50th Annual ASCO Meeting in Chicago.
The dosing frequency of zoledronic acid can be reduced by 67% without compromising efficacy and safety in women with breast cancer and bone metastases.
Maha Hussain, MD, from the University of Michigan Comprehensive Cancer Center, discusses the possibility of ETS gene fusions acting as a predictive biomarker for prostate cancer.
For patients with less than a year to live, the discontinuation of statins may increase the median time-to-death and improve quality of life.
Silvia Formenti, MD, The Sandra and Edward H. Meyer Professor of Radiation Oncology chair, Radiation Oncology, NYU Langone Medical Center, associate director, Radiation Oncology, Perlmutter Cancer Center at NYU Langone, discusses a trial that examines concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer (TNBC)
Anna C. Pavlick, DO, associate professor, Hematology and Medical Oncology, medical director, Clinical Trials Office, Perlmutter Cancer Center at NYU Langone, discusses a phase II trial exploring low-dose cyclophosphamide and ipilimumab in metastatic melanoma.
Jason J. Luke, MD, instructor, Department of Medicine, Harvard School of Medicine, staff physician, medical oncologist- melanoma, Dana-Farber Cancer Institute, discusses the controversy behind the COMBI-d trial results.
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses a long-term safety analysis of the COU-AA-302 study, which he presented at the 2014 AUA Annual Meeting.
Deepak A. Kapoor, MD, from Integrated Medical Professionals, PLLC, discusses the inclusion of radium-223 in the AUA guideline for castration resistant prostate cancer (CRPC).
Analysis of trends in prostate-specific antigen (PSA) dynamics suggested that PSA growth rates, as well as the amount of PSA-level increase due specifically to cancer, might offer a means of distinguishing aggressive, potentially fatal prostate cancer from clinically inconsequential tumors.
Christopher P. Evans, MD, professor, chairman, Department of Urology, University of California at Davis School of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of an analysis of patients with and without visceral disease defined as liver and/or lung metastases who participated in the PREVAIL study.
Men given the GnRH antagonist degarelix because their PSA level rose after primary therapy fared at least as well on an intermittent medication schedule as on a continuous schedule
A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology, a retrospective study of patient data showed.
E. David Crawford, MD, from University of Colorado at Denver, discusses a study presented at the 2014 AUA Annual Meeting that analyzed intermittent androgen deprivation with degarelix.
Daily treatment with the PDE-5 inhibitor tadalafil (Cialis) led to a significant decrease in loss of penile length among men who had undergone bilateral nerve-sparing radical prostatectomy.
Testicular self-examination remains highly cost-effective despite a negative recommendation from the United States Preventive Services Task Force (USPSTF), a cost-utility analysis suggested.
When it comes to detecting prostate cancer accurately and noninvasively, dogs may be ahead by a nose.
Michael Aberger, MD, resident physician, University of Kansas Medical Center, discusses a cost analysis of testicular self-examinations.
In the age of social media, simply having a website isn't enough. To keep existing patients and attract new ones, large urology group practices need to build websites that are connected to social media outlets at every turn, said Peter M. Knapp, Jr, MD.
Self-reported physical activity significantly improved the odds that a person would not die of bladder cancer, a review of a national health information database showed.
